{"analyses":[{"ciLowerLimit":"0.18","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.55","groupDescription":"Stratified analysis based on the strata of IC levels per IxRS, the number of prior chemotherapy regimens per IxRS, and histology per eCRF.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.31","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.21","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.55","groupDescription":"Unstratified Analysis","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.34","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.9","upperLimit":"7.6","value":"6.2"},{"comment":"Data not reported because the upper limit of confidence interval (CI) was not estimable due to higher number of censored participants.","groupId":"OG001","lowerLimit":"10.0","upperLimit":"NA","value":"16.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"58"}],"units":"Participants"}],"description":"DOR:Duration from the first tumor assessment that supports the participant's objective response to PD or death due to any cause,whichever occurs first.CR:complete disappearance of all target lesions and non-target disease.All nodes,both target and non-target,must decrease to normal. No new lesions.PR: At least a 30% decrease in the sum of the diameters of all target and all new measurable lesions, taking as reference the baseline sum of diameters, in the absence of CR.Participants who have not experienced PD at the time of analysis were censored at the time of the last tumor assessment.Participants with no post-baseline tumor assessment were censored at the randomization date plus 1 day.PD:at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm,progression of existing non-target lesions,or presence of new lesions.DOR was estimated using KM methodology.","dispersionType":"95% Confidence Interval","groups":[{"description":"Docetaxel 75 milligrams per square meter (mg/m\\^2) was administered intravenously (IV) on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.","id":"OG000","title":"Docetaxel"},{"description":"Atezolizumab 1200 mg was administered IV on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.","id":"OG001","title":"Atezolizumab"}],"paramType":"MEDIAN","populationDescription":"The PP-ITT analysis set.","reportingStatus":"POSTED","timeFrame":"From first objective response of CR or PR to PD or death due to any cause, whichever occurred first (up to approximately 2.25 years)","title":"Duration of Response (DOR) as Determined by Investigator Using RECIST v1.1: PP-ITT","type":"SECONDARY","unitOfMeasure":"Months"}